Details of the Drug Combinations

General Information of This Drug (ID: DMJSVRL)

Drug Name

JM216 DMJSVRL

Synonyms

129580-63-8; JM 216; satraplatin(jm216); Satraplatin (USAN/INN); C081294; YHI-601; C6H13N.C4H6Cl2O4Pt.H3N; Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-; 4023AH; AKOS015914237; BMS-182751; BC679462; FT-0601550; D05807; Bis(acetato-O)amminedichloro(cyclohexanamine)-pt; 580S638; I14-43013; Platinum (lV) cis-dichloro-trans-bis(acetato-O)ammine(cyclohexanamine)

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Erlotinib + JM216	DCGVQ8I	Erlotinib	Lung Cancer	[2]
------------------------------------------------------------------------------------

References

1	Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol. 1999 Dec;17(12):3822-7.
2	ClinicalTrials.gov (NCT00370383) A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)